Accel, Happinet, Asahi Yukizai and others raise earnings forecasts

フィスコ··JP·Read original
3▲5 ▼3Impact / 5
Summary · why it matters

In the Tokyo stock market on the 9th, Accel, Happinet, Asahi Yukizai, NSD, and NaITO were bought after raising their earnings forecasts the previous day. Accel hit the daily limit-up with pro-rata allocation, lifting its first-half operating profit from a previous forecast of 970 million yen to 1.33 billion yen and its full-year figure from 1.2 billion yen to 2.29 billion yen, while also raising its annual dividend from 41 yen to 79 yen. Happinet raised its first-half operating profit from 7.8 billion yen to 13.5 billion yen; Asahi Yukizai lifted its first-half figure from 3.9 billion yen to 5.5 billion yen and its full-year figure from 8.5 billion yen to 12 billion yen, and increased its annual dividend from 130 yen to 180 yen. NSD raised its first-half operating profit from 8.4 billion yen to 8.9 billion yen and its full-year figure from 19.5 billion yen to 20.1 billion yen, while NaITO revised its full-year operating profit forecast upward from 400 million yen to 1.25 billion yen. Meanwhile, MediciNova hit the daily limit-down with pro-rata allocation after its Phase 2 clinical trial of MN-001 failed to show statistical superiority, and Chugai Pharmaceutical fell sharply for a second day after Roche decided to discontinue development of GYM329, a candidate treatment for obesity.

Impact on assets 8

Health Care▼ · 2 stocks
MediciNova Inc
MNOV
▼ NegativeTechnologyrelevance

Phase 2 trial of MN-001 failed to show statistical superiority, sending shares limit-down.

Roche Holding AG
ROP
▼ NegativeTechnologyrelevance

Roche decided to discontinue development of GYM329, an obesity treatment candidate.

Climate Adaptation & Water▲ · 1 stocks
ASAHI YUKIZAI CORPORATION
4216
▲ PositiveCapitalrelevance

Asahi Yukizai raised its first-half and full-year operating profit forecasts and lifted its annual dividend.

Biotech & Genomic Medicine▼ · 1 stocks
Chugai Pharmaceutical Co., Ltd.
4519
▼ NegativeTechnologyrelevance

Roche decided to discontinue development of GYM329, an obesity treatment candidate, hitting Chugai shares for a second day.

Semiconductors▲ · 1 stocks
Axell Corporation
6730
▲ PositiveCapitalrelevance

Axell raised its first-half and full-year operating profit forecasts and lifted its annual dividend.

Consumer Discretionary▲ · 1 stocks
Happinet Corporation
7552
▲ PositiveCapitalrelevance

Happinet raised its first-half operating profit forecast from 7.8 billion yen to 13.5 billion yen.

Robotics & Physical AI▲ · 1 stocks
Naito & Co., Ltd.
7624
▲ PositiveCapitalrelevance

NaITO raised its full-year operating profit forecast from 400 million yen to 1.25 billion yen.

Cloud & Digital Infrastructure▲ · 1 stocks
NSD Co., Ltd.
9759
▲ PositiveCapitalrelevance

NSD raised its first-half and full-year operating profit forecasts.

© 2026 MarketIVNews